Table 1.
Therapeutic strategies to target ACE-2 receptor and S-protein interaction in SARS-CoV-2 infection
| Type | Target | Description |
|---|---|---|
| Synthetic compounds | ||
| RS504393 | ACE-2 and S-protein of SARS-CoV-2 | Treated for lung injury and bronchial wall thickening [20] |
| KT185 | S-protein of SARS-CoV-2 | Anti-inflammatory [21] |
| TNP | ACE-2 | Tyrosine kinase inhibitor [22, 23] |
| GNF-5 | ACE-2 | Kinase inhibitor [24] |
| GR127935 hydrochloride hydrate | ACE-2 | Vasoconstriction monitoring [25] |
| Eptifibatide acetate | ACE-2 | Protects lung injury and inflammation [26] |
| Monoclonal antibody | ||
| 47D11 | Entry of SARS-CoV-2 | Human antibody specific to SARS-CoV-2 [27] |
| Antiviral agents | ||
| HrsACE-2 | ACE-2 | Recombinant protein [28] |
| CR3022 | S-protein | Neutralizing antibody [29] |
| Umifenovir (Arbidol) | Endocytosis | Membrane fusion inhibitor [30, 31] |
| EK1C4 | Endocytosis | Pan-coronavirus fusion inhibitor [32] |
| Camostat mesilate | TMPRSS2 | Serine protease inhibitor [33, 34] |
| Nafamostat | TMPRSS2 | Serine protease inhibitor [30, 35] |
| Bromhexine hydrochloride | TMPRSS2 | Mucolytic drug [36] |
| PAI-1 | TMPRSS2 | Serine protease inhibitor [37] |
| Chloroquine | Cell fusion/virus | Drug for autoimmune disease [38] |